CN-105
Star0
Identification
- Generic Name
- CN-105
- DrugBank Accession Number
- DB18345
- Background
CN-105 is a neuroprotective pentapeptide with the sequence Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 713.846
Monoisotopic: 713.440889171 - Chemical Formula
- C28H55N15O7
- Synonyms
- Ac-VSRRR- NH2
- External IDs
- CN 105
- CN-105
- CN105
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- W525NLS74J
- CAS number
- 1632243-07-2
- InChI Key
- ZPSIKZCGZCSUNF-HVTWWXFQSA-N
- InChI
- InChI=1S/C28H55N15O7/c1-14(2)20(39-15(3)45)25(50)43-19(13-44)24(49)42-18(9-6-12-38-28(34)35)23(48)41-17(8-5-11-37-27(32)33)22(47)40-16(21(29)46)7-4-10-36-26(30)31/h14,16-20,44H,4-13H2,1-3H3,(H2,29,46)(H,39,45)(H,40,47)(H,41,48)(H,42,49)(H,43,50)(H4,30,31,36)(H4,32,33,37)(H4,34,35,38)/t16-,17-,18-,19-,20-/m0/s1
- IUPAC Name
- (2S)-5-carbamimidamido-2-[(2S)-5-carbamimidamido-2-[(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-2-acetamido-3-methylbutanamido]-3-hydroxypropanamido]pentanamido]pentanamido]pentanamide
- SMILES
- CC(C)[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Prevention POCD - Postoperative Cognitive Dysfunction / Postoperative Delirium (POD) 1 2 Completed Supportive Care Cerebral Hemorrhage 1 2 Completed Treatment Cerebral Hemorrhage 1 2 Recruiting Treatment Cerebral Hemorrhage 1 1 Completed Treatment Cerebral Hemorrhage 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -6.6 Chemaxon pKa (Strongest Basic) 12.43 Chemaxon Physiological Charge 3 Chemaxon Hydrogen Acceptor Count 16 Chemaxon Hydrogen Donor Count 16 Chemaxon Polar Surface Area 394.52 Å2 Chemaxon Rotatable Bond Count 24 Chemaxon Refractivity 211.77 m3·mol-1 Chemaxon Polarizability 72.96 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at September 19, 2023 17:19 / Updated at September 21, 2023 13:10